Explore

Rapid ReadRapid Read
Broad Genomic Testing Extends Lifespan for Advanced Lung Cancer Patients, Study Finds

Broad Genomic Testing Extends Lifespan for Advanced Lung Cancer Patients, Study Finds

Research published in JNCCN—Journal of the National Comprehensive Cancer Network indicates that comprehensive genomic sequencing of lung cancer tumors before initial treatment can prolong the lives of patients with advanced disease. The study, which analyzed electronic health record data from approximately 280 U.S. academic and community oncology clinics between 2016 and 2022, involved tens of thousands of patients. It found that broad genomic sequencing (BGS), which examines hundreds of genes, led to an average increase of two months in overall survival for patients with stage IIIB–IV non-small cell lung cancer (NSCLC) compared to more limited biomarker testing. Patients undergoing BGS lived a median of 16 months versus 14 months for those with focused testing. Additionally, BGS resulted in higher biomarker positivity (60% vs. 22%) and greater use of targeted therapies (19% vs. 16%). However, BGS did not show improved outcomes in the matched second-line cohort.
Rapid ReadRapid Read
City of Hope Receives $11 Million Gift to Advance Personalized Cancer Treatment and AI Research

City of Hope Receives $11 Million Gift to Advance Personalized Cancer Treatment and AI Research

City of Hope, a prominent cancer research and treatment organization in the United States, has been granted an $11 million philanthropic gift from the Simms/Mann Family Foundation. This substantial donation is earmarked to accelerate research in personalized cancer prevention, diagnosis, and treatment. The investment will specifically support advancements in genomics, artificial intelligence (AI), and microbiome science. A key outcome of this gift will be the establishment of the Simms/Mann Family Foundation Precision Oncology Program in Southern California, creating a permanent funding source for high-priority research projects and emerging scientific opportunities. Additionally, the gift will fund two endowed academic chairs: one for cancer microbiome research and another for clinical cancer genomics, with the latter to be filled through a recruitment process.
Rapid ReadRapid Read
Ezra Cohen Raises Critical Questions on Pancreatic Cancer Vaccine Efficacy and T-Cell Response

Ezra Cohen Raises Critical Questions on Pancreatic Cancer Vaccine Efficacy and T-Cell Response

Ezra Cohen, Chief Medical Officer of Oncology at Tempus Labs, has highlighted key questions regarding the future of pancreatic cancer vaccines, specifically in the context of the randomized phase 2 AMPLIFY-7P trial. The trial investigated a lymph node-targeted, mKRAS-specific amphiphile vaccine. While the primary endpoint of median disease-free survival (DFS) was not met (23.8 months with camupepimut versus 21.2 months with observation), a strong immune response was observed, with 98.9% of evaluable vaccinated patients developing mKRAS-specific T-cell responses. Crucially, stronger mKRAS-specific T-cell responses were associated with longer DFS. Cohen's questions focus on why some patients did not exhibit a robust immune response and how to enhance this response to maximize the vaccine's efficacy. The trial also noted encouraging subgroup findings, suggesting improved DFS among patients with negative baseline ctDNA and those without prior radiotherapy, alongside a favorable safety profile.
TrendlineTrendline
Greens Powders and Multivitamins Serve Distinct Nutritional Roles, Experts Advise

Greens Powders and Multivitamins Serve Distinct Nutritional Roles, Experts Advise

Greens Powders and Multivitamins Serve Distinct Nutritional Roles, Experts Advise
Rapid ReadRapid Read
Rockefeller University Scientists Discover Gut Antibodies Protect Against Colon Cancer by Regulating Cell Division

Rockefeller University Scientists Discover Gut Antibodies Protect Against Colon Cancer by Regulating Cell Division

Scientists at Rockefeller University have discovered that immunoglobulin A (IgA) antibodies in the gut play a crucial role in preventing colon cancer. Their research, published in Nature, found that mice lacking IgA developed more than twice the usual number of colon tumors. The study elucidated that IgA antibodies bind to cells lining the gut, specifically epithelial cells, and prevent them from dividing too rapidly. This uncontrolled cell division is a precursor to cancer. Senior author Daniel Mucida, head of Rockefeller's Laboratory of Mucosal Immunology, highlighted that this finding reveals a natural defense mechanism that restrains cell division before tumors can form. The research also showed that administering oral doses of IgA to IgA-deficient mice eliminated their increased risk of developing tumors.
Rapid ReadRapid Read
AnCan Hosts Video Chat on Hi-Risk/Recurrent/Advanced Prostate Cancer, Featuring Rick Davis

AnCan Hosts Video Chat on Hi-Risk/Recurrent/Advanced Prostate Cancer, Featuring Rick Davis

AnCan, an organization focused on cancer support, hosted a video chat on November 10, 2026, specifically addressing Hi-Risk/Recurrent/Advanced Prostate Cancer. Rick Davis was a participant in this video chat. The discussion covered various topics relevant to prostate cancer patients, including treatment decisions for newly diagnosed high-risk individuals, the efficacy of different therapies like darolutamide and denosumab, and the consideration of clinical trials such as the LEGION-100 SYNC-T trial. The chat also touched upon side effects from treatments, such as urinary issues post-radiation therapy and fatigue from darolutamide. AnCan emphasized that views expressed are solely the opinion of the AnCan Foundation, its moderators, and participants, and that the organization does not provide medical advice, encouraging participants to consult their medical teams.
Rapid ReadRapid Read
Guardant Health Expands Liquid Biopsy Capabilities with AI and Epigenomics for Cancer Treatment

Guardant Health Expands Liquid Biopsy Capabilities with AI and Epigenomics for Cancer Treatment

Guardant Health has introduced new applications for its Guardant360 Liquid test, significantly expanding its capabilities for treatment selection in advanced breast and lung cancers. These advancements integrate genomics, epigenomics, and artificial intelligence (AI) through the InfinityAI platform to provide a more comprehensive view of tumor biology. The expanded test now includes two epigenomic predictors designed to identify patients who may benefit from selective estrogen receptor degraders (SERDs) in advanced breast cancer or immune checkpoint inhibitor monotherapy in advanced non-small cell lung cancer (NSCLC). Notably, the lung cancer application can epigenomically identify PD-L1 negative patients without requiring a tissue sample, combining tumor microenvironment characterization with tumor mutational burden and microsatellite instability for immunotherapy assessment. Additionally, these new features can detect ALK fusions and MTAP deletions that genomic liquid testing alone might miss, offering d...
Rapid ReadRapid Read
Scientists Discover Method to Mitigate Dangerous Side Effects of Cancer Immunotherapy

Scientists Discover Method to Mitigate Dangerous Side Effects of Cancer Immunotherapy

Scientists have identified a potential method to make cancer immunotherapy safer by stabilizing immune cells that regulate immune responses. Immunotherapy, a cancer treatment that harnesses the body's immune system to attack cancer cells, can sometimes cause severe side effects where the immune system attacks healthy tissues. These immune-related adverse events, particularly with immune checkpoint inhibitors, affect 20% to 40% of patients, with up to 25% experiencing severe reactions leading to hospitalization and treatment cessation. There are currently no FDA-approved treatments for these side effects. A study published in Cell, led by Abigail Overacre-Delgoffe, Ph.D., assistant professor at the University of Pittsburgh School of Medicine, found that unstable regulatory T cells are a key driver of this inflammation. Her team successfully reversed inflammation in mice by blocking a specific protein in these cells and observed that diet and the gut microbiome influence the severity of these reactions.
Rapid ReadRapid Read
Reps. Carson and Wittman Introduce Bipartisan Bill for National Young Adult Cancer Strategy

Reps. Carson and Wittman Introduce Bipartisan Bill for National Young Adult Cancer Strategy

Reps. André Carson (D-Ind.) and Rob Wittman (R-Va.) have introduced bipartisan legislation in the U.S. House of Representatives to establish the Asal Sayas National Strategy on Young Adult Cancers Act. This bill aims to create the first national strategy specifically addressing cancers in adults aged 18 to 49. The Colorectal Cancer Alliance is leading a national effort to gather support for this bill, encouraging patients, caregivers, advocates, and organizations to sign up and help ensure its passage. The proposed legislation would mandate the National Institutes of Health (NIH) to develop a comprehensive strategy within 18 months of the bill becoming law. This strategy would involve mapping current research, launching a national education campaign to raise awareness of symptoms and risk factors, setting research priorities for causes, biomarkers, early detection, and new treatments, and reducing barriers to clinical trial participation for young adults. Companion legislation was previously introduced in ...
Rapid ReadRapid Read
Dr. C. Ola Landgren to Receive PMWC Pioneer Award for Advancing Minimal Residual Disease in Multiple Myeloma

Dr. C. Ola Landgren to Receive PMWC Pioneer Award for Advancing Minimal Residual Disease in Multiple Myeloma

C. Ola Landgren, M.D., Ph.D., director of Sylvester Myeloma Institute at Sylvester Comprehensive Cancer Center, will receive the Precision Medicine World Conference (PMWC) Pioneer Award in January 2027. This recognition is for his significant contributions to advancing minimal residual disease (MRD) as an earlier and more precise measure of treatment effectiveness in multiple myeloma. MRD refers to the tiny number of cancer cells that remain during remission, detectable only by highly sensitive laboratory methods. Dr. Landgren's work has been instrumental in helping new therapies demonstrate effectiveness more quickly, potentially accelerating their availability to patients. His team is also leading research into bispecific T-cell therapies, including strategies to safely deliver these treatments and manage side effects like cytokine release syndrome. This research extends to other cancers, such as lymphoma and rare gynecologic neuroendocrine cancers, demonstrating a continuous cycle of measurement, learni...
Rapid ReadRapid Read
University of Cincinnati Hosts Summit on AI's Role in Reshaping Healthcare and Lowering Costs

University of Cincinnati Hosts Summit on AI's Role in Reshaping Healthcare and Lowering Costs

Professionals in artificial intelligence and healthcare recently convened at the University of Cincinnati for a summit focused on how AI can transform medicine, from disease diagnosis to reducing patient costs. The event addressed the rising healthcare expenses, with a national survey by Marsh McLennan indicating an 8% average increase in employer-sponsored health plan costs for the coming year, the highest since 2003. Summit organizer Jamison DeAngelis expressed optimism that AI could enhance the efficiency of healthcare systems, ultimately leading to lower patient costs. Dr. Kelly Kohen, director of the AI Biolab Digital Futures at the University of Cincinnati, highlighted AI's potential to deliver personalized treatment tailored to individual needs. Dr. Alex Tobin, a radiologist, emphasized AI's capability to meticulously analyze medical images, potentially identifying patterns that could predict optimal therapies or patient outcomes. Kyle Frye, CEO of Cortex AI, noted that AI tools could also assist in...
ReutersReuters
CAR-T trial deaths do not deter lupus patients hoping for a cure

CAR-T trial deaths do not deter lupus patients hoping for a cure

By Julie Steenhuysen CHICAGO, Nov 11 (Reuters) - Lupus patients struggling with the debilitating disease are lining up to try experimental CAR-T therapies even after the recent deaths of four patients in clinical trials for a variety of autoimmune diseases, according to doctors who treat the life-